Opinion|Videos|February 5, 2025
Recent FDA Approvals in NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how FDA approvals have expanded options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), with pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec-vncg offering new immunotherapy and gene therapy approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the treatment landscape of NMIBC changed in recent years to provide better options for patients?
- Provide an overview of recent FDA approvals, including for the treatment of high-risk, BCG-unresponsive NMIBC (pembrolizumab [PD-1 inhibitor], nogapendekin alfa inbakicept-pmln [immunotherapy], and nadofaragene firadenovec-vncg [gene therapy]).
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
2
Higher saturated fat intake associated with increased mortality in nonmetastatic prostate cancer
3
NeoBLAST trial tests active surveillance after complete response in MIBC
4
What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed
5